Get the Stockscreener App
40.97
3.60%
-1.53
Urogen Pharma Ltd stock is traded at $40.97, with a volume of 421.25K.
It is down -3.60% in the last 24 hours and up +15.67% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
See More
Previous Close:
$42.50
Open:
$42.52
24h Volume:
421.25K
Relative Volume:
0.53
Market Cap:
$2.00B
Revenue:
$140.49M
Net Income/Loss:
$-153.49M
P/E Ratio:
-14.87
EPS:
-2.7551
Net Cash Flow:
$-175.90M
1W Performance:
+1.84%
1M Performance:
+15.67%
6M Performance:
+104.85%
1Y Performance:
+127.61%
1-Day Range:
$40.78
$42.89
1-Week Range:
$40.23
$43.93
52-Week Range:
$15.86
$43.93
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
40.97 | 2.00B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Jefferies | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Price to earnings forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to earnings forward of UroGen Pharma Ltd. – FWB:UR8 - TradingView
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
(URGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
URGN Maintained by Guggenheim -- Price Target Raised to $42 - GuruFocus
URGN stock trades steady as UroGen revenue grows and pipeline advances - Ad-hoc-news.de
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders - simplywall.st
Enterprise value to revenue forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Price to sales forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat (NASDAQ:URGN) - Seeking Alpha
Price to earnings forward of UroGen Pharma Ltd. – MUN:UR8 - TradingView
UroGen Pharma (URGN) AGM 2026 Summary - Quartr
What's Driving Investor Interest in UroGen Pharma (URGN) Ahead of Goldman Sachs - Kavout | AI
UroGen Pharma (URGN) Rallies On FDA Clearance As Valuation Questions Grow - simplywall.st
Urogen Pharma stock hits 52-week high at 41.45 USD By Investing.com - Investing.com South Africa
ETFs Investing in UroGen Pharma Ltd. Stocks - TradingView
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027 - Barchart.com
Urogen Pharma stock hits 52-week high at 41.45 USD - Investing.com
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news - Investing.com UK
H.C. Wainwright reiterates UroGen Pharma stock rating on patent news By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
URGN Maintained by Oppenheimer -- Price Target Raised to $50 - GuruFocus
Oppenheimer Adjusts Price Target on UroGen Pharma to $50 From $40, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises UroGen Pharma stock price target to $50 on sales outlook - Investing.com Canada
UroGen Pharma (URGN) Secures Patent Approval for Bladder Cancer Treatment - GuruFocus
Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44 - 富途牛牛
UroGen receives US patent allowance for bladder cancer treatment - Investing.com UK
Should I Buy URGN (UroGen Pharma Ltd.) | AI Analysis, Technical & News Insights - Kavout | AI
UroGen receives US patent allowance for bladder cancer treatment By Investing.com - Investing.com Nigeria
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 - The Manila Times
UroGen Receives New U.S. Patent Allowance Expected to - GlobeNewswire
UroGen patent allowance covers bladder cancer care without tumor resection - Stock Titan
URGN Stock Price, Quote & Chart - ChartMill
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer - BioBuzz
UroGen receives FDA clearance for bladder cancer trial By Investing.com - Investing.com Nigeria
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run - The Motley Fool
UroGen Pharma (URGN) Is Up 5.8% After FDA Clears IND For UGN-501 Phase 1 Trial - Sahm
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares By Investing.com - Investing.com Australia
Form 4 Urogen Pharma Ltd For: 10 July By Investing.com - Investing.com India
UroGen Pharma CMO Mark Schoenberg sells $400,000 in shares - Investing.com
UroGen Pharma (URGN) CMO Mark Schoenberg sells 10,000 shares via Rule 10b5-1 plan - Stock Titan
Is UroGen Pharma (URGN) Undervalued Following FDA Clearance For UGN 501? - Sahm
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):